FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response.

Bogatyrova, Olga; Mattsson, Johanna S M; Ross, Edith M; Sanderson, Michael P; Backman, Max; Botling, Johan; Brunnström, Hans; Kurppa, Pinja; La Fleur, Linnéa; Strell, Carina; Wilm, Claudia; Zimmermann, Astrid; Esdar, Christina; Micke, Patrick

Bogatyrova, Olga; Mattsson, Johanna S M; Ross, Edith M; Sanderson, Michael P; Backman, Max; Botling, Johan; Brunnström, Hans; Kurppa, Pinja; La Fleur, Linnéa; Strell, Carina; Wilm, Claudia; Zimmermann, Astrid; Esdar, Christina; Micke, Patrick.

Affiliation

Bogatyrova O; Translational Innovation Platform Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany.
Mattsson JSM; Dept. of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Ross EM; Translational Medicine, Merck KGaA, Darmstadt, Germany.
Sanderson MP; Translational Innovation Platform Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany.
Backman M; Dept. of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Botling J; Dept. of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Brunnström H; Division of Pathology, Lund University, Skåne University Hospital, Lund, Sweden.
Kurppa P; Dept. of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
La Fleur L; Dept. of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Strell C; Dept. of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Wilm C; Translational Innovation Platform Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany.
Zimmermann A; Translational Innovation Platform Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany.
Esdar C; Translational Innovation Platform Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany.
Micke P; Dept. of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Electronic address: patrick.micke@igp.uu.se.

Eur J Cancer ; 151: 136-149, 2021 07.

Article in En | MEDLINE | ID: mdl-33984662

Subject(s)

Carcinoma, Non-Small-Cell Lung/metabolism; DNA Methylation; Epigenesis, Genetic; Lung Neoplasms/metabolism; Receptor, Fibroblast Growth Factor, Type 1/metabolism; Animals; Antineoplastic Agents/pharmacology; B7-H1 Antigen/metabolism; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/genetics; Carcinoma, Non-Small-Cell Lung/immunology; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms/drug therapy; Lung Neoplasms/genetics; Lung Neoplasms/immunology; Lymphocytes, Tumor-Infiltrating/immunology; Lymphocytes, Tumor-Infiltrating/metabolism; Mice, Inbred NOD; Mice, SCID; MicroRNAs/genetics; MicroRNAs/metabolism; Molecular Targeted Therapy; Receptor, Fibroblast Growth Factor, Type 1/antagonists & inhibitors; Receptor, Fibroblast Growth Factor, Type 1/genetics; T-Lymphocytes/immunology; T-Lymphocytes/metabolism; Tumor Microenvironment; Xenograft Model Antitumor Assays

Key words

Cancer immunity; FGFR1; Non-small cell lung cancer; Promoter methylation; miRNA

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / DNA Methylation / Epigenesis, Genetic / Receptor, Fibroblast Growth Factor, Type 1 / Lung Neoplasms Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Year: 2021 Type: Article

Fulltext

XML

PubMed Links

Search on Google